|
|
2016 Featured Talks » Anti-ErbB3 therapies – what do we know to date
Birgit Schoeberl, part 1 from MCC Industry Relations on Vimeo.
Birgit Schoeberl, part 2 from MCC Industry Relations on Vimeo.
Birgit Schoeberl, PhD
Head of Research and Development
Merrimack Pharmaceuticals
Dr. Birgit Schoeberl is an internationally recognized leader in the application of Systems Biology to biology and drug development. At Merrimack, an oncology focused biotech company in Cambridge, MA, she leads early stage drug discovery and development. She joined Merrimack Pharmaceuticals in 2003 after doing postdoctoral training at MIT and was instrumental to building the company and its current pipeline. Dr. Schoeberl holds an M.S. in chemical engineering from the University of Karlsruhe, Germany, and a Ph.D. from the Max-Planck-Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany.
|
